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Abstract: Several histopathological variants of colorectal carcinoma can be distinguished,
some associated with specific molecular profiles. However, in routine practice, ninety/ninety-five
percent of all large bowel tumors are diagnosed as conventional adenocarcinoma, even though they are
a heterogeneous group including rare histotypes, which are often under-recognized. Indeed, colorectal
cancer exhibits differences in incidence, location of tumor, pathogenesis, molecular pathways and
outcome depending on histotype. The aim is therefore to review the morphological and molecular
features of these rare variants of intestinal carcinomas which may hold the key to differences in
prognosis and treatment.
Keywords: colorectal cancer histotypes; signet ring cell carcinoma; medullary carcinoma;
lymphoepitelioma-like carcinoma; cribriform/comedo-type carcinoma; micropapillary carcinoma; clear
cell carcinoma; hepatoid carcinoma; adenocarcinoma with osseous metaplasia; rhabdoid carcinoma
1. Introduction
Colorectal cancer (CRC) is the third most frequent malignant neoplasm worldwide. The CRC risk
increases with age, as the majority of cases are diagnosed in patients with more than 50 years of age.
CRCs exhibit biological differences in both pathogenesis and molecular pathways reflecting different
incidences, sidedness and outcome [1,2]. Most CRC are located in the sigmoid colon/rectum, but the
proportion of carcinomas in the right colon increases with age [3].
Three kinds of alterations are involved in CRC development: (1) chromosomal instability (CIN);
(2) microsatellite instability (MSI); (3) CpG island methylator phenotype (CIMP). A different association
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between these pathogenetic alterations determines distinct molecular pathways: (i) traditional,
(ii) alternative and (iii) serrated [1]:
(i) The traditional pathway is based on APC and KRAS mutations (by CIN alterations). These neoplasms
usually involve the left colon.
(ii) The alternative pathway is characterized by a CIMP-low phenotype, predominant KRAS and
occasional BRAF mutations, with no CIN. The prognosis of these CRC is aggressive.
(iii) The serrated pathway is characterized by BRAF mutations and epigenomic instability (CIMP-high).
These lesions are located mainly in the right colon with MSI morphology (mucinous, medullary
and tumours with intraepithelial lymphocytes) or MSS with a serrated morphology (eosinophilic
cytoplasm, epithelial serration and tufts and vescicular basal nuclei) [1,3].
Tumor development through the traditional pathway is relatively slow (5–20 years), probably
due to the fact that the initial events occur in the fully differentiated cells of the colonic crypt.
APC mutations, generally, are detected in the cells of the upper crypt compartment according to the
top-down morphogenetic model [4]. The causal events underlying the serrated pathway, however,
may take place in the cells of the lower crypt compartment which are less differentiated and rapidly
progressive [5]. This could explain the morphologic heterogeneity of tumors arising in the right colon,
in older patients which are usually BRAF mutated. These CRCs are thought to develop rapidly and
may in part explain interval cancers [6]. These new insights into the molecular pathogenesis of CRC
have contributed to the distinction of right- and left-sided CRCs, identifying them as two distinct
clinical, pathological and molecular entities [7]. This distinction is especially useful considering the
impact which sidedness may have on treatment choice.
Several epithelial histopathological variants of CRC can be distinguished, some associated with
specific molecular profiles. In routine practice, 90–95% of all large bowel tumors are diagnosed as
classic adenocarcinoma, however this group is actually a heterogeneous population including rare
histotypes which are often underdiagnosed but which may collectively reach up to 50% of CRCs in
histologically classified series (Figure 1). Indeed, a frequent downfall in large studies is that CRCs
are collected regardless of histotype with no importance being given to rare histotypes. The aim is
to review the morphologic and molecular features of these rare histotypes which may be seen as
pure/prevalent forms (Table 1) or as composite/mixed morphologically heterogeneous neoplasms
(in which each separate morphological entity should be reported and quantified). The understanding
of the morphological complexity of a group of tumors which are often all placed together in the
CRC basket is especially important for non-pathology clinical colleagues or researchers who may
not be aware or appreciate the subtleties of morphology (phenotype) with its possible molecular
implications (genotype).
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Figure 1. Pie chart showing the frequency of colorectal carcinomas by histologic type.Figure 1. Pie chart showing the frequency of colorectal carcinomas by histologic type.
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Table 1. Clinico-pathologic and immune-molecular characteristics of rare type colorectal carcinomas.
Histotype Mean Age Site Prognosis# Main Diagnostic Criteria Immunoprofile Molecular Profile
Serrated Adenocarcinoma (SA) 67 Right colon andrectum Aggressive
Epithelial serrations +/− tufts; eosinophilic cytoplasm;
vescicular nuclei
KRASmut BRAFmut
MSI
Mucinous (colloid)
adenocarcinoma (MA) 60 Right colon
Similar to
conventional Abundant extracellular mucin in more than 50% MMRd, PDL1+
KRASmut BRAFmut,
MSI
Signet ring cell carcinoma (SRC) 65 No site predilection Aggressive Signet ring cells in more than 50% MMRd, PDL1+ KRAS
mut BRAFmut,
MSI
Medullary carcinoma (MC) 70 Right colon Favourable
Solid growth pattern with circumscribed tumor borders;
tumor cells with a syncytial appearance; conspicuous
intra and peri tumor lymphocytes.
MMRd, CDX-2−, CK20+,
calretinin+ MSI, BRAF
mut
Lymphoepitelioma-like (LELC) 62 No site predilection Favourable Poorly differentiated carcinoma with abundantintratumour infiltrating lymphocytes; presence of EBV MMRd EBV+
Cribriform comedo-type
adenocarcinoma (CC-type) 56 No site predilection Aggressive
Tightly packed neoplastic glands and cribriform
architecture and large glands with central necrosis CK20+, CDX-2+, MUC2+
Micropapillary carcinoma (MPA) 69 Right colon andrectum Aggressive
Clusters with lacunar space of more than 5 neoplastic
cells; inverse polarity
Inverted MUC1, MUC2−,
E-cadherin altered pattern
TP53mut, KRASmut,
BRAFmut, CIN
Low -grade tubuloglandular
carcinoma (LGTGA) 42 No site predilection Favourable
Tubular architecture composed of neoplastic glands with
little atypia MMRd (MLH1d)
MSI, KRASmut,
IDH1mut
Villous carcinoma (VC) 66 Left colon Favourable Villous architecture in >50% KRASmut
Squamous/Adenosquamous
carcinoma (SCC/ASC) 60 Right colon Aggressive
Squamous differentiation either pure or composite with
glandular component p63+, CK5/6+
Clear cell
carcinoma
Mullerian-mCCC 52 Exclusively rectum Favourable Clear cells in more than 50%; endometriosis or pregnancy CK20−, CK7+, CEA−, CA125+
Intestinal-iCCC 61 No site predilection Aggressive Clear cell in more than 50% CK20+, CK7−, CEA+, CDX-2+) KRASmut, MSI
Hepatoid carcinoma (HepAC) 50 Rectum Aggressive Neoplastic cells with hepatoid appearence in solid,trabecular o pseudoacinar architectural patterns
AFP+ (also serum), Glypican-3+,
CK18+, CK19+, CEA+, Hep Par1
+ (40%)
Primary Choriocarcinoma (pChC) 54 Left colon Aggressive Syncytiotrophoblast-like cells β-HCG (also serum)
Rhabdoid carcinoma (RhC) 70 Right colon Aggressive Rhabdoid cells >5% CK20−, Vimentin+, CDX-2−,INI1−, CROCC reduction signals.
BRAFmut, MSI,
CROCCmut
Carcinoma with osseous
metaplasia (COM) 58 Left colon
Similar to
conventional
Presence of osseous metaplasia in a conventional
adenocarcinoma
Spindle cell or mesenchymal
carcinoma* (SpCC) 70
Left colon and
Rectum Aggressive
Biphasic carcinoma with a spindle-cell sarcomatoid
component (cytokeratin +); may have giant cells Vimentin+, CK+ (focal)
Undifferentiated carcinoma (UC) 70 No site predilection Aggressive Evidence of epithelial differentiation with minimal orwithout gland formation
CK+, absence of other
differentiation markers
* Pleomorphic carcinoma is considered within this type. # Prognosis is compared to conventional colorectal adenocarcinoma. MSI—microsatellite instability; MMRd—mismatch repair
protein deficiency; CK—cytokeratins; EBV—Ebstein-Barr virus; CIN—Chromosomal instability.
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2. Serrated Adenocarcinoma (SA)
2.1. Background
Following the first description of five CRCs histologically resembling serrated polyps by Jass
and Smith [8], Mäkinen et al. reported twenty-seven CRCs associated with an adjacent serrated
adenoma [9]. They noted that such cases exhibited distinctive clinical, histological and molecular
features, suggesting that serrated adenocarcinomas (SAs) may be considered a distinct entity, probably
representing an end-point of the serrated pathway. Several subsequent studies have confirmed the
clinico-pathologic and molecular differences between SA and conventional CRC [10,11], recognizing
SA as a distinct CRC subtype in the 2010 WHO classification. SA can be identified either by the
presence of a residual serrated polyp or by its peculiar histologic characteristics, even when precursor
lesions are no longer visible [10,12]. Considering this definition, SA accounts for 5.8–12% of all CRCs
and up to 17% of proximal CRCs.
2.2. Clinical Presentation
The mean age of patients with SA ranges between 65 and 70 years; gender prevalence is
controversial, with a prevalence of females in Finnish studies [8,11,12] and of males in Spanish
series [10].
2.3. Sidedness
Most SA are located in either the right colon (47–57%) or the rectum (15–29%).
2.4. Morphologic Diagnostic Criteria
The histologic criteria for SA diagnosis include: epithelial serrations and tufts, abundant
eosinophilic or clear cytoplasm, vesicular basal nuclei with chromatin condensation around the
nuclear envelope, easily distinguishable nuclei and preserved polarity, absence or less than 10%
necrosis of the total surface area and, within mucinous areas, the presence of cell balls and papillary
rods [12]. Importantly, serrations of SAs are composed of epithelium with or without basement
membrane, but lack the fibro-vascular cores seen in non-serrated CRCs (Figure 2A). Three growth
patterns have been described-serrated, mucinous and trabecular, the latter being characteristic of
poorly differentiated SAs, which may be challenging to recognize.
2.5. Molecular Alterations
Gene expression and methylome profiling analysis has highlighted a clear distinction between
SAs and conventional CRCs [13–15], showing higher representation of morphogenesis-, hypoxia-,
cytoskeleton- and vesicle transport-related functions in SA. Among the most relevant differentially
expressed genes, hypoxia-inducible factor 1-alpha (HIF-1α), fascin 1, the anti-apoptotic gene
hippocalcin and annexin A10, are specifically upregulated in SA and, therefore, have been proposed
as immunohistochemical markers for SA diagnosis. KRAS and BRAF mutations are common in
SA, being found in 33% and 45% of cases, respectively, and may contribute to stabilize HIF-1α [11].
BRAF mutation, in particular, is strongly associated with serrated morphology in CRCs. Up to 20% of
SA harbor microsatellite instability (MSI).
2.6. Prognosis
Garcia-Solano et al. [10] demonstrated that SA patients more frequently presented lymph node
metastases (52%) and they showed a less favorable prognosis compared to conventional CRCs,
especially in the case of left-side SA. In addition, SAs are characterized by higher frequency of adverse
histologic features at the invasive front, such as high-grade tumor budding and weak peritumoural
Cancers 2019, 11, 1036 6 of 26
lymphocytic infiltration [16]. Interestingly, Zhu et al. highlighted that high PD-L1 expression by SAs is
frequent (25%) and associated with poor survival [17].Cancers 2019, 11, x FOR PEER REVIEW 7 of 28 
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3. Mucinous (Colloid) Adenocarcinoma (MA)
3.1. Background
Primary mucinous (colloid) colorectal adenocarcinoma (MA), is defined by the presence of more
than 50% of extracellular mucin component containing malignant epithelium, according to the WHO
2010 classification criteria [18]. It constitutes approximately 10–15% of all CRCs and it is associated
with peculiar clinico-pathological and prognostic features if compared to conventional CRCs [19].
3.2. Clinical Presentation
The mean age of presentation is 60 years (range from 10 to 93 years) with low female gender
prevalence. Symptoms do not differ from those of conventional CRC however MA is often diagnosed
in advanced stage, it is generally of larger size and it is associated with frequent loco-regional lymph
node involvement and peritoneal implants [20].
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3.3. Sidedness
MA is more often localized to the right colon [21], including caecum, ascending colon and proximal
transverse colon.
3.4. Morphologic Diagnostic Criteria
Histology shows abundant extracellular mucin associated with ribbons or tubular structures
of neoplastic epithelium (Figure 2B). Single cells, including signet ring cells, may be found floating
within the mucin or attached to the adjacent stromal wall. Mucinous morphological changes in post
neoadjuvant treatment cancers must not be interpreted as MA [22]. Presence of tumor infiltrating
lymphocytes (TILs) is frequent, may show a Crohn-like appearance and is frequently associated with
MSI [21].
3.5. Molecular Genotype
MA is one of the histotypes associated with MSI [20], both in sporadic and in Lynch syndrome
associated CRCs. In sporadic CRCs, MSI is due to epigenetic silencing of the promoter region of
mismatch repair (MMR) genes (predominantly MLH1) by CpG island hypermethylation. Diversely,
Lynch syndrome associated patients show germline mutational inactivation of genes encoding the
MMR proteins MLH1, MSH2, MSH6 or PMS2 and MA has a 22–40% prevalence in this setting.
Furthermore the high mutational load of MA MSI-H, with its high production of tumor specific
neoantigens, represents a strong immunogenic factor which explains the presence of TILs. MA has
a greater incidence (65%) of KRAS mutations, compared to other CRC sub-types without mucin
production, and often shows BRAF mutation.
3.6. Prognosis
There is no definitive evidence regarding prognostic differences between MA compared to
conventional CRC. Indeed, the Literature is a well of conflicting data about prognosis and overall
survival; in this context sidedness may have an impact (poorer prognosis in rectal MA versus colonic
MA) [21]. A recent study has shown that there is no difference in prognosis, adjusted for stage, between
non mucinous conventional adenocarcinoma and adenocarcinomas with mucin production of any
percentage [20] making the 50% cut off debatable.
4. Signet Ring Cell Carcinoma (SRC)
4.1. Background
Primary colorectal signet ring cell carcinoma (SRC) is a rare histotype representing about 0.7–1%
of all CRCs. It was first described by Laufman and Saphir in 1951 [23] and is defined as a CRC variant
with > 50% of tumour cells showing prominent intracytoplasmic mucin [18].
4.2. Clinical Presentation
This subtype of CRC occurs in younger individuals compared to conventional CRC (range at
diagnosis 48 to 70 years) and it seems to occur more frequently in females.
4.3. Sidedness
SRC has been reported to be more frequently localized in the right colon, including caecum,
ascending colon and proximal transverse colon even though discrepancies regarding site of tumor are
present in the literature [24].
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4.4. Morphologic Diagnostic Criteria
SRC is characterized by more than 50% of cells with prominent intracytoplasmic mucin and
displacement of the nucleus (Figure 2C) [18]. These cells can be found associated with two main
histological patterns of growth: (a) infiltrative, mucin poor (linitis plastica-like) pattern, often associated
with adverse histological features such as vascular and perineural invasion; (b) mucin rich pattern with
signet ring cells floating in large pools of mucin. There is no standardized method to separate SRC into
the two morphological groups [25]. Adenocarcinomas with presence of less than 50 % of signet ring
cells are defined as “adenocarcinomas with signet ring cell component” [18]. As for MA, high intra
and peritumoral TILs are seen, especially in MSI associated SRC.
4.5. Molecular Genotype
SRC share molecular features with MA: they have a higher frequency of KRAS and BRAF
mutations compared with conventional CRC, which are associated with a shorter median OS compared
to KRAS and BRAF wild-type patients. SRC are often MSI-H tumors and have CpG island methylator
phenotype-high (CIMP-H). Though SRC are a clinically aggressive tumours, MSI-H status correlates
with a better prognosis and should be considered low grade tumors [26]. Two different molecular
genotypes in SRC have been recognized: (a) the hypermethylated genotype with MSI-H, CIMP-H,
BRAF-V600E, PDL1+, predominantly located in the right colon, which may be treated with immune
checkpoint inhibitor therapy; (b) the hypomethylated genotype, predominantly located in left colon [27].
4.6. Prognosis
SRC is diagnosed at a more advanced stage with transmural extension, loco-regional lymph
node metastases and peritoneal dissemination [28]. SRC has been considered an extremely aggressive
tumor and is considered as an independent histologic prognostic factor of less favorable outcome and
high risk of death [28]. However, as stated above, due to its heterogeneity and different molecular
genotypes, SRC should not always be considered predictor of poor prognosis: SRC MMR/MSI-H
should be considered as low grade tumors whereas SRC MSS/MSI low show aggressive behavior even
though these data are still being debated. Another feature of promising prognostic value is represented
by mucin phenotype. Some literature data have demonstrated that mucin-poor SRC have a worse
prognosis, with an aggressive clinical outcome if compared with mucin-rich SRC [25].
5. Medullary Carcinoma (MC)
5.1. Background
The term “medullary (adeno)carcinoma” (MC) of the colon was first employed by Jessurun et al. in
1999 [29]. Subsequently, small series of MCs were reported and described as a distinct subgroup of CRCs
showing minimal glandular differentiation and intense intratumoral and peritumoral lymphocytic
infiltration [29–31]. These tumors were also characterized by proximal location, diploid flow cytometric
nuclear DNA content and low levels of p53 protein expression. In addition, they demonstrated near
always MSI by molecular analysis and better survival rate than other poorly differentiated CRCs [29–31].
Further studies confirmed and expanded these initial observations [32].
5.2. Clinical Presentation
The mean age of patients with MC is similar to that of patients with conventional CRC,
with a prevalence in the female gender. MCs account for a small percentage (2.2%) of all CRCs,
but represents about 20% of large bowel poorly differentiated adenocarcinomas [33]. MCs may be
sporadic or develop in patients with Lynch syndrome.
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5.3. Sidedness
The large majority of MCs are located in the proximal colon [32,33].
5.4. Morphologic Diagnostic Criteria
MC is characterized by neoplastic cells with vesicular nuclei, prominent nucleoli and abundant
eosinophilic cytoplasm, arranged in solid sheets and exhibiting prominent infiltration by intraepithelial
lymphocytes (Figure 2D). The percentage of the tumor area which should exhibit medullary features in
order to classify a tumor as medullary is not specified. In a recent meta-analysis, Pyo and coworkers [33]
reported a great variation in the histologic criteria utilized for the definition of MC among different
studies. In addition some Authors considered presence of MMR deficiency necessary for the diagnosis
of MC [31,32]. For these reasons, the histological diagnosis of MC results poorly reproducible and the
diagnostic criteria for differentiating MCs from non-medullary poorly differentiated carcinomas still
need to be clarified [34].
5.5. Molecular Genotype
Most MCs are MSI-H at molecular analysis and show loss of expression of MMR proteins (generally
MLH1 and PMS2) by immunohistochemistry. Moreover, MCs often demonstrate MLH1 promoter
methylation and BRAF-V600E mutation. On the contrary, TP53 and KRAS mutations occur much less
frequently in MC than in conventional CRC [33]. Immunophenotypically, MCs often show loss of
CDX2 and cytokeratin (CK) 20 expression and positivity for calretinin [35,36]. The clinicopathologic
and molecular features of MC are mainly related to their MMR deficient phenotype. However, recent
studies indicate that MCs differ from the other types of MSI-H CRCs especially regarding the tumor
immunoregulatory microenvironment [37,38].
5.6. Prognosis
MCs have a more favorable clinical outcome as compared to conventional poorly differentiated
adenocarcinomas but not with respect to CRCs when considered globally [33]. Recent studies suggest
that MCs seem to behave more aggressively than other MSI-H CRCs [39].
6. Lymphoepitelioma-Like Carcinoma (LELC)
6.1. Background
Lymphoepitelioma-like carcinoma (LELC) is an undifferentiated carcinoma with prominent
lymphoid stroma, found most frequently in the nasopharynx and associated with Epstein Bar Virus
(EBV)-infection, although various other sites have been described [40]. In the gastrointestinal tract,
the stomach is the most frequent site, while only 9 case have been described in the colon-rectum [41].
6.2. Clinical Presentation
Patient’s age is variable (range 25–86 years) with no gender predilection. Clinical presentation is
unremarkable [40].
6.3. Sidedness
LELCs are present in the whole colon-rectum with the most frequent site being the sigmoid colon.
6.4. Morphologic Diagnostic Criteria
LELCs are composed of poorly differentiated cells arranged in solid nests, tubules and trabeculae
with poorly demarcated, infiltrative margins. Inflammatory lymphoid infiltrate is extremely abundant
and, differently from medullary carcinoma, is intratumoral rather than peritumoral, permeating
between neoplastic cells (Figure 3A) [41]. Lymphoid follicles with germinal centers are usually present.
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Figure 3. Haematoxylin and Eosin stained sections of rare type colorectal carcinomas. (A) Lymphoepitelioma-
like carcinoma: poorly differentiated cells (red arrow) arranged in solid nests, tubules and trabeculae
with poorly demarcated, infiltrative margins; intratumoral lymphoid infiltrate is extremely abundant.
Scale bar 200 micron. (B) Cribiform comedo-type carcinoma: cribriform gland (yellow arrow) with
central necrosis comedo-like (yellow asterisk). Scale bar 400 micron. (C) Micropapillary Carcinoma:
small, tight round to oval cohesive clusters of neoplastic cells (>5 cells) floating in clear spaces (double
circle red-black), without endothelial lining and with no evidence of inflammatory cells. Scale bar
200 micron. (D) Low grade tubulo-glandular carcinoma: very well-differentiated invasive glands with
uniform circular or tubular profiles (blue arrow) with bland cytologic atypia. Scale bar 400 micron.
6.5. Molecular Genotype
While nasopharyngeal and gastric LELCs are frequently associated with EBV, only in 3/9 colonic
cases has this association been reported [42]. Of interest, 2 cases were associated with ulcerative
colitis [43] and a further 2 colonic LELCs showed microsatellite instability (1 due to epigenetic
methylation of MLH1 promoter and 1 Lynch Syndrome associated) [41,44].
6.6. Prognosis
Prognosis of LELCs has been suggested to be more favorable than conventional CRC, but data are
few; the role of inflammation, EBV and MSI status requires further investigation [40].
7. Cribriform Comedo-Type Carcinoma (CC-Type)
7.1. Background
According to the largest reported series by Lino-Silva et al. of 18 cases [45], cribriform comedo-type
(CC-type) CRC represents 7.3% of colonic adenocarcinomas.
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7.2. Clinical Presentation
Mean age at diagnosis is similar to that of conventional CRC with a predominance in the male sex.
7.3. Sidedness
CC-type can be found all along the large bowel with no reported site predilection.
7.4. Morphologic Diagnostic Criteria
CC-type CRC is defined as a tumor having “extensive large cribriform glands with central necrosis
analogous to breast adenocarcinoma” [18] with tightly packed neoplastic glands, minimal intervening
stroma and cribriform architecture. Both histologic hallmarks (cribriform and comedo) are necessary for
the CC-type diagnosis (Figure 3B). Its immunoprofile is similar to that of conventional adenocarcinoma
(CK20+, CDX2+, MUC2+) [45]. CC-type CRC may be found in combination with micropapillary
pattern [46].
7.5. Molecular Genotype
The molecular genotype of CC-type CRC has not been specifically investigated however it is
usually microsatellite stable with a CIMP profile [47].
7.6. Prognosis
CC-type CRC is mainly diagnosed at advanced stage (III, IV) and often shows lymphovascular
invasion and nodal metastases. Patients with CC-type CRC have shorter overall survival compared
to patients with conventional CRC [45]. Furthermore, the presence of CC-type features in pT1
adenocarcinomas is predictive of nodal metastases [48].
8. Micropapillary Adenocarcinoma (MPA)
8.1. Background
Micropapillary adenocarcinoma (MPA) was firstly reported in 2005 [49] and its incidence varies
from 9% to 19% of CRC [50]. Pure micropapillary carcinoma is rare, while a micropapillary component
ranging between 5 and 30% in an otherwise conventional adenocarcinoma is the most frequent
occurrence [51].
8.2. Clinical Presentation
MPA is more frequent between 53 and 72 years [52,53], while it is rare in young patients [54].
8.3. Sidedness
This variant occurs more frequently in the rectum and the right colon [50,55].
8.4. Morphology
At histopathology, MPA is defined by the presence of small, tight, round to oval, cohesive clusters
of neoplastic cells floating in clear spaces, lined by delicate strands of fibro-collagenous stroma without
endothelial lining and with no evidence of inflammatory cells (Figure 3C). This aspect is probably due
to peritumoral tissue retraction and to the reversed polarity of the tumor cell in the clusters (“inside-out”
growth pattern) [50,56]. This latter aspect is confirmed by their inverted immunohistochemical MUC1
expression, lack of MUC2 stain and loss or altered pattern of E-cadherin stain. Interestingly, tumour
cells express mesenchymal markers (vimentin) and nuclear localization of SMAD4, which suggests
epithelial-mesenchymal-transition [56–58]. At electron microscopy, neoplastic cells show microvilli on
their outer surface, with secretory activity toward the surrounding stroma [52]. Micropapillary features
are often maintained in the nodal metastases. Poorly differentiated clusters of tumor cells (PDC) [59],
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recently described at the periphery or within the tumor mass, display a morphologic similarity to the
micropapillary carcinoma, and according to some authors [57], the micropapillary pattern and poorly
differentiated clusters may represent the same biological phenomenon.
8.5. Molecular Genotype
MPA shows frequent TP53, KRAS and BRAF-V600E mutations, and it develops via classical
chromosomal instability (CIN pattern), while MSI is infrequent [52,58].
8.6. Prognosis
MPA is characterized by unfavourable prognosis, being frequently diagnosed at advanced stage
with high occurrence of lymph node or distant metastases [49,51,56].
9. Low Grade Tubuloglandular Adenocarcinoma (LGTGA)
9.1. Background
Low-grade tubuloglandular adenocarcinomas (LGTGA) represent approximately 10% of inflammatory
bowel disease (IBD) associated CRCs and less than 1% of all CRCs [60].
9.2. Clinical Presentation
A slightly higher prevalence in men (1.4:1) has been reported and these tumors are generally
diagnosed in middle-aged or older adults (median age 41.5 years, range 28–58) [60]. In some cases,
tumors may only be identifiable on random sections of the resected specimen without macroscopic
evidence of a cancerous growth. One third of described LGTGA coexisted with one or more synchronous
adenocarcinomas of conventional histologic types. LGTGA are more frequently observed in ulcerative
colitis than Crohn’s disease and the median duration of IBD before surgery is usually more than
20 years.
9.3. Sidedness
Distributed roughly equally on either side of the splenic flexure, LGTGA has been described to
occur also in the terminal ileum [61].
9.4. Morphologic Diagnostic Criteria
LGTGAs are characterized by very well-differentiated invasive glands with uniform circular or
tubular profiles and they are usually surrounded by flat or polypoid low-grade dysplasia. The neoplastic
epithelia show bland cytologic atypia resembling overlying low-grade or indefinite dysplastic crypts
and the tumor is associated with little to no stromal desmoplasia (Figure 3D). Heterogeneous tumors
containing well-defined regions of LGTGA and adjacent conventional carcinoma are also seen, with the
conventional component typically located in deeper regions of the tumor, suggesting histologic
progression from a lower to a higher grade of neoplasia. Immunohistochemically LGTGA present
frequent co-expression of CK7 and CK20 (69%).
9.5. Molecular Genotype
IDH1 mutations were observed in three LGTGA of a series of eight cases, and in two of these
three cases a concomitant activating KRAS mutation was also present [62]. High prevalence of loss of
MLH1 expression by immunohistochemistry (55%) has been reported supporting an association with
MSI-H status [60].
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9.6. Prognosis
Limited information is available; generally a favorable prognosis has been described unless
a synchronous conventional colorectal carcinoma is also present.
10. Villous Carcinoma (VC)
10.1. Background
Villous carcinoma (VC) is a rare (1%), well differentiated subtype of CRC, resembling villous
adenoma on the surface and it is also known as “adenoma-like adenocarcinoma” or “‘papillary
adenocarcinoma” [63–65].
10.2. Clinical Presentation
VC shows male predominance; the median age at diagnosis is 66 years (range 48 to 83 years),
which is comparable to conventional CRC [63].
10.3. Sidedness
Contrasting data is present in the literature; a study has shown a predilection for the rectum and
sigma (almost the 80% of the cases).
10.4. Morphologic Diagnostic Criteria
VC is an invasive carcinoma with architectural and cytologic features resembling villous adenoma.
The neoplastic epithelium is more frequently characterized by low-grade atypia and intraglandular
papillary projections associated with an expansile growth pattern are usually seen (Figure 4A).
The presence of neoplastic epithelial islands surrounded by desmoplastic stroma may help in the
diagnosis [63] which may be challenging in biopsy specimens. The lesions often have a pushing border
involving the wall of the colon. Most lesions have non-adenoma-like areas, which can display dilated
glands filled with mucin at the leading edge of the tumor or may be represented by well-differentiated
CRC of no particular subtype [66].
10.5. Molecular Genotype
In a series of 24 cases, KRAS mutations were detected in 14 (58%) cases and MSI was present in 4
of 17 (24%) [66].
10.6. Prognosis
VC shows favorable prognosis with a lower rate of nodal and distant metastases compared to
conventional CRC [63].
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11. Squamous (SCC) and Adenosquamous Carcinoma (ASC)
11.1. Background
Both lesions are rare, representing 0.1–0.5% of primary CRC [67,68]. For squamous cell carcinoma
(SCC), diagnosis requires the exclusion of any involvement of cloacogenic or anal squamous carcinoma,
the absence of any squamous cell carcinoma elsewhere and thorough extensive sampling of the lesion
to exclude adenosquamous carcinoma (ASC).
11.2. Clinical Presentation
SCC is associated with ulcerative colitis, chronic colo-cutaneous fistula, schistosomiasis and
colonic duplication [67]; ASC can occur in patients with ulcerative colitis [68] and both may cause
paraneoplastic hypercalcemia [69,70]. There is no significant difference in sex, age, and ethnicity
between SCC/A an co ventional CRC.
11.3. Sidedness
ASC typically arises in the right colon, whereas SCC is most commonly located in the proximal
colon and rectum.
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11.4. Morphologic Diagnostic Criteria
SCC is morphologically similar to squamous cell carcinomas occurring in other organs and
basaloid or acantholytic subtypes have been described (Figure 4B). ASC, on the other hand, resembles
conventional colorectal adenocarcinoma, but with areas of squamous differentiation, either admixed or
distinct. Both histotypes are positive for CK5/6 and p63 in the squamous component [71].
11.5. Molecular Genotype
HPV infection does not appear to play a role. No information is available on the molecular
landscape of these histotypes [72,73].
11.6. Prognosis
Both SCC and ASC have higher metastatic rates and worse prognosis than conventional CRC and
tumor stage is often advanced at onset [67,68].
12. Primary Clear Cell Carcinoma (CCC)
12.1. Background
Primary colorectal clear cell carcinoma (CCC) is a rare CRC type with 37 cases described in
the Literature since 1944 [74]. Two tumor types of CCC can be recognized on the basis of different
immunoprofiles: (a) intestinal CCC (iCCC) and (b) Müllerian CCC (mCCC) [74].
12.2. Clinical Presentation
The mean age of onset is 56.5 years (range of 27–89); in particular women are affected at a younger
age than males (51.9 years versus 61.5 years) [74].
12.3. Sidedness
All colorectal sites may be involved however the left side is more frequent. mCCCs arise
exclusively in the rectum (77%) or sigma (23%) of women [74].
12.4. Morphologic Diagnostic Criteria
The diagnostic hallmark of CCC is the presence of more than 50% of clear cells (Figure 4C) as
polygonal cells with a central nucleus, columnar cells with an eccentric nucleus and/or round/oval
cells with abundant cytoplasm and inconspicuous marginally located nucleus similar to lipocytes or
lipoblasts. Both a “pure form” and a “composite” form, admixed with a conventional CRC, have been
described. iCCC diagnostic criteria are: (a) composite CCC with conventional adenocarcinoma
or presence of adenomatous component [75], (b) absence of adjacent endometriosis, (c) intestinal
immunoprofile (CK20+, CK7−, CEA+, CDX-2+) [74,76]. mCCC diagnostic criteria are: (a) evidence of
Müllerian origin immunoprofile (CK7+, CK20−, CEA−, CA125+) with or without histologically
recognizable endometriotic foci in close proximity; (b) exclusion of origin from other primary
sites [74,77].
12.5. Molecular Genotype
iCCC show predominantly (80%) KRAS mutations and proficient MMR profile. mCCC have not
been studied as yet.
12.6. Prognosis
While iCCC shows aggressive behavior (mean overall survival of 13.8 months): 36% are diagnosed
with locally advanced disease and 33% show distant metastases at onset. mCCC, on the other hand,
is thought to be an indolent tumor [74].
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13. Hepatoid Adenocarcinoma (HepAC)
13.1. Background
HepAC is a rare extrahepatic adenocarcinoma mimicking hepatocellular carcinoma (HCC),
first described in 1970 [78]. In the gastrointestinal tract, HepAC is more frequent in the stomach [79],
possibly due to a common foregut embryologic origin, while only 42 cases affecting the bowel have
been described.
13.2. Clinical Presentation
A comprehensive review [80] has shown that intestinal HepAC commonly occurs in younger
patients (around 50 years of age) with a male predominance. Very high serum Alpha Fetoprotein (AFP)
levels are reported in almost all cases. Furthermore, an association with long standing inflammatory
bowel disease has been reported (8/42 patients), suggesting its possible role in HepAC cancerogenesis.
13.3. Sidedness
About 70% of reported cases arise in the colon (50%) or rectum (20%) while 30% of cases involve
the small bowel.
13.4. Morphologic Diagnostic Criteria
HepAC is characterized by large polygonal-shaped cells, with granular eosinophilic cytoplasm,
prominent nucleoli and trabecular and pseudo-acinar growth patterns (Figure 4D). Morphology
resembles HCC and this can cause diagnostic pitfalls, especially when presenting as liver metastases.
Immunohistochemistry is mandatory to reach a correct diagnosis with AFP, glypican-3, cytokeratins 18,
19 and carcinoembryonic antigen (CEA) positivity in nearly all cases [80,81] while Hep Par1 positivity is
reported only in about 40% of cases. Little information is available on intestinal markers, with frequent
CK20 negativity; CDX-2 positivity is reported only in a few cases (the majority of cases were not tested).
13.5. Molecular Genotype
Little in know about the molecular profile and pathogenesis of colorectal HepAC is still an enigma.
Possible hypotheses include derivation from dispersed fetal cells within the tumor or the activation of
silenced liver specific genes during carcinogenesis [82].
13.6. Prognosis
HepAC is aggressive with markedly worse prognosis compared to conventional CRC. The majority
of patients (80%) present in stages III or IV and distant metastases (mainly hepatic) at onset are reported
in 40% of patients. Patients generally relapse and succumb within the first year. Radical surgery with
liver resection of metastatic disease, followed by chemotherapy, is considered the first choice treatment
though HepAC seems to show no response to conventional CRC chemotherapy [80–82].
14. Primary Colorectal Choriocarcinoma (pChC)
14.1. Background
Primary choriocarcinoma is a highly malignant neoplasm with trophoblastic differentiation
which typically occurs either associated with pregnancy or as ovarian/testicular germ cell tumors.
Extra-gestational, non-gonadal primary choriocarcinomas are exceedingly rare and may be found in
different sites such as the mediastinum, retroperitoneum or lung; in the digestive system, the stomach is
the most frequent site while only 29 primary colorectal choriocarcinomas (pChC) have been described
in the literature.
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14.2. Clinical Presentation
Patients are usually younger than conventional CRC (median 54 years, range 12–74; 45% are
<50 years of age) with no gender predilection. Symptoms are similar to conventional CRC however
most patients have increased serum βHCG levels (which may be used as a biomarker) [83]. Three cases
have been found to be associated with Crohn’s disease or ulcerative colitis.
14.3. Sidedness
pChC are equally distributed along the length of the colon-rectum (34% in the right colon; 41% in
the left colon; 24% in the rectum).
14.4. Morphologic Diagnostic Criteria
pChC are usually large, solid masses with necrosis and haemorrhages. At histology, these tumors
present as either: mixed adenocarcinomatous and choriocarcinomatous components (72% of cases)
or show pure choriocarcinomatous features (28% of cases). The defining βHCG immunopositive
component is characterized by biphasic solid nests and trabeculae of mononucleated cells with clear
cytoplasm and pleomorphic cells with abundant vacuolated or eosinophilic cytoplasm and single or
multiple vescicular nuclei with conspicuous nucleoli (Figure 5A). Diffuse vascular invasion, extensive
necrosis and numerous typical/atypical mitoses are also seen.
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14.5. Molecular Genotype
Three theories of development have been proposed [84,85]: (1) primordial germinal cells migrated
to anomalous sites during embryogenesis; (2) primary unknown gestational or gonadal lesions;
(3) the most accredited theory is dedifferentiation of a preexisting colonic adenocarcinoma [86].
In consideration of the few cases reported no information is available on specific molecular findings.
14.6. Prognosis
Disease progression is generally rapid with early metastatic dissemination (often at diagnosis):
distant metastases predominantly show pure choriocarcinomatous features. Chemotherapeutic
regimens targeting either colorectal germ cell tumors have been proposed with variable results,
nonetheless survival is less than 1 year from onset [87].
15. Rhabdoid Colorectal Carcinoma (RhC)
15.1. Background
Rhabdoid colorectal carcinoma (RhC) is a rare and lethal neoplasm morphologically similar
to malignant extrarenal rhabdoid tumor. Thirty-four cases of colorectal RhC have up till now been
described [88].
15.2. Clinical Presentation
RhC occurs in adulthood (31–87 years) around the 7th decade without gender predilection.
15.3. Sidedness
These tumors predominantly affect the right colon [89].
15.4. Morphologic Diagnostic Criteria
The diagnostic hallmark of this neoplasm is the presence of “rhabdoid” cells characterized by
a large, eccentrically located nuclei, prominent nucleoli [88], abundant eosinophilic cytoplasm which,
at ultrastructural analysis shows aggregates of intermediate filaments (Figure 5B) [90]. The extent
and distribution of the rhabdoid component is highly variable, ranging from “composite carcinomas,”
in which the rhabdoid elements are associated with adenocarcinoma, to “pure” rhabdoid carcinomas
without an evident conventional component [88]. A quota of RhCs show loss of immunoexpression of
INI1; however this may also be seen in a small group (11%) of conventional CRC [91].
15.5. Molecular Genotype
RhCs show predominant BRAF mutations and MSI-H molecular profile. In this specific genotypic
asset, alterations in chromatin remodeling (SWI/SNF or SMARCB1) complex [91,92] and in the
centrosome structure (Ciliary Rootlet Coiled Coil; CROCC) have been reported as major genetic
determinants of rhabdoid pathogenesis [89].
15.6. Prognosis
RhC prognosis is very aggressive with an overall survival of 7.9 months regardless of stage [89].
The presence of lamellipodia in CROCC-mutated RhC may explain their aggressive behavior [90].
16. Carcinoma with Osseous Metaplasia (COM)
16.1. Background
Primary CRC with presence of heterotopic bone formation, initially described by Hasegawa [93]
in 1923 and subsequently reported by Dukes [94] in 1939, is a rare event with a suggested incidence
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of 0.4% in rectal cancers. From 1990 to 2019, 21 cases have been described and the largest published
series [95] is composed of just three cases, with incidence hypothesized to be as low as 0.15%.
16.2. Clinical Presentation
No gender predilection has been reported and age at onset is variable (29 to 90 years). Symptoms
and endoscopy are no different to conventional CRC, while calcification/bone formation may be seen
at imaging [96].
16.3. Sidedness
COM is more frequently diagnosed in the rectum (about 40% of cases), followed by left and right
colon and appendix.
16.4. Morphologic Diagnostic Criteria
Osseous metaplasia, recognized as foci of bone formation in the stroma, with calcification, osteoid
matrix, osteoclasts and osteoblasts, has been reported in conventional CRC or, less frequently, in other
colorectal histotypes, such as serrated carcinoma (Figure 5C). A possible intriguing explanation of
osseous metaplasia is that undifferentiated stromal cells transform into osteoblasts under the stimulus
of bone morphogenetic proteins (BMP 5 and 6) produced by cancer cells [97].
16.5. Molecular Genotype
Mutations in different codons of KRAS have been detected, however data are too few to suggest
a role of KRAS mutations in COM.
16.6. Prognosis
Data on prognosis are scarce, however osseous metaplasia does not seem to affect prognosis [96].
17. Spindle Cell Carcinoma (SpCC)
17.1. Background
Spindle cell carcinoma (SpCC) (alternatively named mesenchymal or sarcomatoid carcinoma) is
a rare variant of CRC, with less than 20 cases reported up to now [98–100].
17.2. Clinical Presentation
SpCC has mean age at presentation similar to that of conventional CRC with no gender
predilection [98–100].
17.3. Sidedness
SpCC shows a slight predominance in the left colon and rectum [98].
17.4. Morphologic Diagnostic Criteria
SpCC is defined as a “biphasic carcinoma with a spindle-cell sarcomatoid component in which the
tumor cells are at least focally immunoreactive for keratins” [18]. Although the name carcinosarcoma
has been used interchangeably [99], it should be reserved to tumors with absence of epithelial
differentiation (absence of epithelial markers) in the sarcomatous component [98]. The rarity of SpCC
may be due to its histological similarity to mesenchymal tumors which renders its differential diagnosis
quite challenging without immunohistochemistry.
17.5. Molecular Genotype
The molecular features of this variant have not been specifically investigated.
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17.6. Prognosis
SpCC is associated with low overall survival, with most patients surviving less than 24 months [98–100].
18. Pleomorphic Carcinoma (PlC)
18.1. Background
Pleomorphic adenocarcinoma (PlC) was firstly described in the colon in 1989 [101] with the report
of two cases, and thereafter only a further two cases have been reported [102,103].
18.2. Clinical Presentation
Age of presentation ranges between 67 and 86 years; three patients with pleomorphic CRC were
females and one was a male [101–103].
18.3. Sidedness
Two cases involved the caecum, one was diagnosed in the descending colon and one in the
sigmoid colon [101–103].
18.4. Morphologic Diagnostic Criteria
Histologically, colonic PlC shows pleomorphic gemistocytic giant cells and spindle cells and it
may resemble choriocarcinoma and sarcoma. Positive staining for cytokeratins and absence of staining
for βHCG are helpful to confirm the diagnosis. PlC is not currently listed among CRC variants in the
WHO classification and whether this is a separate entity or whether it may be included together with
spindle cell/mesenchymal carcinomas is unknown but likely.
18.5. Molecular Genotype
Molecular features of this variant have been not investigated.
18.6. Prognosis
Although two patients with pleomorphic carcinoma were reported to have short survival [101,102],
no definitive conclusions on the prognostic value of this variant can be drawn due to its rarity.
19. Undifferentiated Carcinoma (UC)
19.1. Background
Undifferentiated carcinomas (UCs) are colorectal tumors showing no gland formation, but still
presenting features of epithelial differentiation [18]. Some Authors include in this category tumors
showing minimal (generally less than 5%) glandular architecture.
19.2. Clinical Presentation
Patients’ age is similar to conventional CRCs; no gender predilection has been reported.
19.3. Sidedness
UCs occur throughout the colon-rectum but they are more frequently detected in the right
colon [104].
19.4. Morphologic Diagnostic Criteria
UCs consist of sheets of undifferentiated cells showing a variable grade of pleomorphism with
minimal gland formation, mucin production or other lines of differentiation (e.g., squamous etc.) and
for this reason extensive sampling is required (Figure 5D). Sometimes they display a trabecular
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pattern, they are often characterized by an infiltrative pattern of growth and show extensive
necrosis. Positive staining for cytokeratins is required to confirm the diagnosis. Pure UCs are
very rare, but adenocarcinomas containing an undifferentiated component are encountered more often.
UCs should be distinguished from medullary carcinomas.
19.5. Molecular Genotype
Little evidence is present with regards to molecular features.
19.6. Prognosis
UCs are aggressive tumors, showing a low 5-year cancer specific survival [104]. In the setting of
metastatic disease patients with UCs also have a worse prognosis [105].
20. Conclusions
A better recognition and histological characterization of CRC is becoming mandatory as new
molecular pathways which identify tumors with different prognoses and treatment are emerging.
Pathologists are being asked to separate variant CRCs from conventional type CRCs indicating that,
even though we are becoming ever more molecular minded, morphology still plays an important role.
We seem to be “going back to the future”: the more we take the molecular path ahead the more we
seem to rely on the morphological lights which guide our way.
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